To identify rare or hard-to-diagnose diseases that consume healthcare dollars before proper diagnoses are made, HVH analyzes large amounts of disparate health data using sophisticated analytics and predictive modeling. By collecting, aggregating and analyzing the journeys of known patients, HVH is helping to inform early diagnosis and intervention of undiagnosed patients with rare diseases at the metropolitan statistical area (MSA), zip code or physician level.
During the peer review study chronicled in The American Journal of Pharmacy Benefits, HVH used a three-stage process to define the characteristics of patients in the database already being treated for Hereditary Angioedema (HAE), a rare genetic disease that can be fatal. It then used those characteristics to create a model of HAE patients, and used the model to find HAE patients in the database who had not yet been identified.
The study demonstrated the ability of this state-of-the-art predictive analysis to find rare disease patients in a large and complex database, shortening the time to diagnosis and relieving patients of the frustration of going from doctor to doctor without a confirmed diagnosis. These analytical techniques are scalable and can be applied to open and closed healthcare systems large and small.
"Through education to a more targeted group of undiagnosed patients and the physicians who treat them, we have the ability to bring patients suffering from rare and hard-to-diagnose diseases to diagnosis sooner," said Tara Grabowsky, MD, Chief Medical Officer, HVH. "It is particularly critical to accelerate time to diagnosis, as 30 percent of children with rare disease will not live to see their 5th birthdays."
HVH is the only analytics provider in the market that uses proven predictive modeling combined with medical expertise to offer solutions that are clinically meaningful.
To read the peer-reviewed study about HVH's methodology, please download the full report here.
To learn more about HVH, visit www.HVHprecision.com.
HVH is a joint venture built on the partnership between Havas Health, a strategic communications partner to many top biopharma companies, and Vencore, a leader in the defense and intelligence communities with next-gen machine learning and advanced predictive analytics. HVH has offices in Boston, New York and King of Prussia, Pennsylvania. To learn more, visit: www.hvhprecision.com.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/scientific-journal-validates-hvhs-methodology-of-diagnosing-patients-with-rare-diseases-300379224.html
SOURCE HVH Patient Precision Analytics